Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

With detailed imaging and cognitive data, the Northern Ireland Cohort for the Longitudinal Study of Aging highlights the potential of integrating eye scans into broader health research.

Ruth Hogg, PhD, on what retinal imaging can tell clinicians about the brain and body

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS is deputy director at Centre for Eye Research Australia (CERA) and head of macular research at CERA. She is also a professor of ophthalmology at the University of Melbourne and senior retinal specialist at The Royal Victorian Eye and Ear Hospital in East Melbourne, Australia. 

Optical coherence tomography markers—like the ellipsoid zone—are reshaping clinical trials in intermediate age-related macular degeneration, as highlighted at the 2025 International SPECTRALIS Symposium — And Beyond (ISS).

Rethinking end points in AMD: the power of OCT imaging with Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

Ocular Therapeutix showcases innovative retinal disease treatments at the  Clinical Trials Summit 2025 in Las Vegas, featuring presentations and discussions.

Ocular Therapeutix to present at Clinical Trials at the Summit 2025

Videos

Advanced monitoring strategies are overcoming significant obstacles in retinal care, as highlighted at the 2025 International SPECTRALIS Symposium — And Beyond (ISS).

Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times – Clinical Insights for Eye Specialists

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Peapack, NJ-Regulatory authorities governing Europe's Mutual Recognition Process have approved the use of latanoprost ophthalmic solution (Xalatan) as a first-line treatment for lowering  IOP in patients with open-angle glaucoma and ocular hypertension.

First-line therapy: Latanoprost approved for glaucoma use in Europe

First-line therapy: Latanoprost approved for glaucoma use in Europe

Newsletter